Biopharma Demo

See how uploading proprietary data increases drug visibility and validates market demand

Upload Proprietary Drug Data

Share unpublished animal study results and expand your drug's indications

Public Data (Currently Visible)

Drug Name:BIOIO-1001
Phase:Phase 1
Target Gene:NMNAT1
Public Indications:
  • • Type 2 Diabetes
  • • Metabolic Syndrome

Proprietary Data (Not Yet Shared)

Additional Indications:
  • • ALS (Amyotrophic Lateral Sclerosis)
  • • Liver Metastatic Cancer
Animal Study Results:
ALS MODEL:
• triglyceride effect: increased by 40%
• survival: extended by 28%
• motor function: improved
LIVER METASTASIS MODEL:
• tumor burden: reduced by 35%
• mechanism: enhanced NAD+ metabolism in hepatocytes

Impact of Sharing Your Data

When you share unpublished research data (like animal study results showing unexpected indications), you help patients discover potentially life-saving matches they wouldn't find otherwise.

More patients helped = more validated demand = better Phase 2/3 trial decisions.

1.0x

Visibility Boost

Limited to public indication matches only

#4

Search Ranking

Ranked behind competitors with more data

36

Patient Matches

Only diabetes matches found

Market Demand Analytics

Real-time signals showing "if you build it, will they come?"

ALS

Metabolic modulators

127
Patients
45
Physicians
2.4/3
Avg Severity
5
States
Geographic Distribution
FL: 67
CA: 25
NY: 15
MT: 12
NH: 8

Type 2 Diabetes

GLP-1 sensitizers

2,341
Patients
189
Physicians
1.8/3
Avg Severity
5
States
Geographic Distribution
FL: 1234
CA: 456
TX: 408
MT: 145
NH: 98

Diabetic Neuropathy

Sphingolipid modulators

876
Patients
92
Physicians
2.1/3
Avg Severity
5
States
Geographic Distribution
FL: 298
CA: 187
TX: 156
NY: 132
MT: 45

Early Data Sharing Rewards

First-Mover Advantage

Evidence contribution weight decreases by 50% each month to reward early contributors. Share early to maximize your "hash power" and search ranking.

Month 1 (Now):1.0x weight
Month 2:0.5x weight
Month 3:0.25x weight

Premium Placement

Your BIOIO-1001 appears lower in search results for:

  • ALS + low triglycerides
  • Liver metastatic cancer
  • Type 2 diabetes + GLP-1 users

Unlock Full Platform Value

By sharing your unpublished animal study data showing BIOIO-1001's paradoxical triglyceride elevation in ALS models, you'll:

  • ✓Discover 127 ALS patients who could benefit (vs. 0 without data sharing)
  • ✓Claim first-mover advantage for ALS indication before competitors
  • ✓Validate market demand before expensive Phase 2 trials
  • ✓Gain 3.5x visibility boost in all relevant patient searches